Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PerkinElmer Adds Infectious Disease Testing By Acquiring Oxford Immunotec For $591M

Executive Summary

PerkinElmer’s sales and testing capacity will expand the reach of Oxford Immunotec’s proprietary interferon gamma release tuberculosis assay technology.

You may also be interested in...



PerkinElmer To Buy UK-Based Immunodiagnostics For $155M

PerkinElmer will add chemiluminescence products in endocrinology, autoimmunity and diagnostics to its portfolio with the planned buyout of Immunodiagnostics.

Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions

During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.

Abbott Adds New Surgical Tissue Valves

The US FDA approved Abbott’s new Epic Plus stented tissue mitral valve and Epic Plus Supra stented tissue aortic valve.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel